Herschel S. Nachlis
Research Assistant Professor, Department of Government
Senior Policy Fellow and Assistant Director, Rockefeller Center for Public Policy and the Social Sciences
Herschel Nachlis is a Research Assistant Professor in the Department of Government and a Senior Policy Fellow and Assistant Director in the Nelson A. Rockefeller Center for Public Policy and the Social Sciences at Dartmouth.
Contact
Department(s)
Government
Center(s)
The Nelson A. Rockefeller Center for Public Policy
Education
- Ph.D. Princeton University
- M.A. Princeton University
- B.A. Macalester College
Selected Publications
Review of Deborah Stone, Counting: How We Use Numbers to Decide What Matters (Liveright: 2020), Journal of Health Politics, Policy, and Law 47, no. 5 (2022), DOI: 10.1215/03616878-9978145.
"The Supreme Court faces more pandemic questions this term. Here are 4 takeaways from last year's rulings," The Washington Post / Monkey Cage, September 24, 2021 (with Kyle Thomson, Amy Park, and Annika Begley).
"Watch this FDA hearing on Thursday. It'll help ease your Covid-19 anxieties," STAT, October 21, 2020.
"The FDA's Evolving COVID-19 Emergency Use Authorizations: How The Convalescent Plasma Authorization Can Inform Future Vaccine and Therapeutic EUAs," Health Affairs Blog, October 20, 2020, DOI: 10.1377/hblog20201016.659416.
"Emergency Use Authorizations During the COVID-19 Pandemic: Lessons From Hydroxychloroquine for Vaccine Authorization and Approval," JAMA: The Journal of the American Medical Association 324, no. 13 (2020): 1282-1283 (with Kyle Thomson).
"Crisis Governance, COVID-19, and American Policy History," Clio 29, no. 2 (2020): 6, 19-24.
"This is why the federal government has a hard time regulating prescription opioids," The Washington Post / Monkey Cage, January 13, 2019.
"Pockets of Weakness in Strong Institutions: Post-Marketing Regulation, Psychopharmaceutical Drugs, and Medical Autonomy, 1938-1982," Studies in American Political Development 32, no. 2 (2018): 257-291.
Review of David Vogel, The Politics of Precaution: Regulating Health, Safety, and Environmental Risks in Europe and the United States (Princeton: Princeton University Press, 2012), Law and Politics Book Review 23, no. 3 (2014): 135-140.
Selected Media
"Just about everyone in America is finally eligible for a Covid-19 vaccine. Now what?" Vox, 2022
"Emergency Use or Overuse?" The Regulatory Review, 2022
"Federal Judge Strikes Down TSA Mask Mandate On Planes and Public Transit," Healthline, 2022
"New Research Highlights Effect of COVID-19 on Contraceptive Care," Contraceptive Technology Update, 2022
"The Biden administration has been sidelining vaccine experts," The Washington Post, 2021
"Why the FDA Hasn't Approved a COVID Shot yet When Millions Are Vaccinated," Newsweek, 2021
"The FDA approved remdesivir to treat Covid-19. Scientists are questioning the evidence." Vox, 2020
"COVID-vaccine results are on the way — and scientists’ concerns are growing," Nature, 2020
"What Is Emergency Use Authorization for COVID-19 Vaccines and Treatments?" AARP, 2020
"Britain’s emergency rush to a vaccine rollout, explained," The Spinoff, 2020
"EUAs are evolving for the better, expert writes," Regulatory Focus, 2020
"FDA Releases New Guidelines for COVID-19 Vaccine Approval: What to Know," Healthline, 2020
"Lessons Learned — or Not — from Hydroxychloroquine Mishap," IRB Advisor, 2020
"A COVID-19 Vaccine at ‘Warp Speed’ Raises Myriad Ethical Questions," IRB Advisor, 2020
"9 Pharma Companies Join to Release Open Letter Promising COVID-19 Vaccine Safety," Healthline, 2020
NHK Japan, 2020
"We Will Not Have a Vaccine by November," Slate, 2020
KHN Morning Briefing, KHN, 2020
"A Win for Science and Transparency: FDA Publishes New, Strict COVID-19 Vaccine Guidelines," Union of Concerned Scientists, 2020
"In case of emergency finish the trial," This Week In Virology, 2020
"Researchers Suggest Improvements to FDA's Authorization, Approval Process Following EUA for Hydroxychloroquine," Pharmacy Times, 2020
"Covid-19 vaccine makers are pushing back against pressures to deliver by Election Day," Vox, 2020
"Viewpoints: The FDA Isn’t Up To The Task Of Reining In The Opioid Epidemic," KHN, 2019